Dr. Savin on the Evolution of Biosimilars

Michael A. Savin, MD
Published: Saturday, Jun 16, 2018



Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the evolution of biosimilars.

The Europeans are ahead of the United States in terms of biosimilars, Savin explains. This may be because they are more cost driven than American counterparts, he adds.

The United States is being driven toward biosimilars as drug prices continue to increase. Twenty to 30 years ago, tamoxifen was a very expensive drug. Previously, an expensive drug was defined as $200 or $300 per month, he says. Now, physicians prescribe drugs that are much more. Biosimilars may be a means of reigning these costs in, he concludes.


Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the evolution of biosimilars.

The Europeans are ahead of the United States in terms of biosimilars, Savin explains. This may be because they are more cost driven than American counterparts, he adds.

The United States is being driven toward biosimilars as drug prices continue to increase. Twenty to 30 years ago, tamoxifen was a very expensive drug. Previously, an expensive drug was defined as $200 or $300 per month, he says. Now, physicians prescribe drugs that are much more. Biosimilars may be a means of reigning these costs in, he concludes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Bridging the Gaps Around Oncology Biosimilars: Assessing the Potential Impact of Emerging Agents to PracticeSep 29, 20181.5
Advent of Oncology Monoclonal Antibody Biosimilars ‒ A European Perspective OnlineNov 30, 20183.0
Publication Bottom Border
Border Publication
x